Phase II trial of clarithromycin/clofazimine/rifabutin [RHB 104] in patients with Crohn's disease secondary to Mycobacterium avium paratuberculosis infection
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Crohn's disease; Mycobacterium avium paratuberculosis infections
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 12 Mar 2025 According to a RedHill Biopharma media release, pending Type C discussions on path to FDA approval with guidance from FDA expected in expected in Q2/25.